Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002. ,
The MAPK pathway in melanoma, Curr Opin Oncol, vol.20, pp.183-189, 2008. ,
, Implication of CD271 in melanoma BRAF inhibitor resistance 12
, Cell Discovery | www.nature.com/celldisc
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, pp.2507-2516, 2011. ,
Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, vol.363, pp.809-819, 2010. ,
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, vol.366, pp.707-714, 2012. ,
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.468, pp.973-977, 2010. ,
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell, vol.18, pp.683-695, 2010. ,
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, vol.480, pp.387-390, 2011. ,
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, vol.468, pp.968-972, 2010. ,
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, J Clin Oncol, vol.29, pp.3085-3096, 2011. ,
A tumorigenic subpopulation with stem cell properties in melanomas, Cancer Res, vol.65, pp.9328-9337, 2005. ,
Identification of cells initiating human melanomas, Nature, vol.451, pp.345-349, 2008. ,
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, vol.494, pp.251-255, 2013. ,
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha, Cancer Discov, vol.4, pp.1214-1229, 2014. ,
Cell-selective inhibition of NF-kappaB signaling improves therapeutic index in a melanoma chemotherapy model, Cancer Discov, vol.1, pp.496-507, 2011. ,
The IkappaB kinase complex in NF-kappaB regulation and beyond, EMBO reports, vol.15, pp.46-61, 2014. ,
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation, Nature, vol.490, pp.412-416, 2012. ,
Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system, Genes Dev, vol.14, pp.2919-2937, 2000. ,
The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells, PLoS ONE, vol.9, p.92596, 2014. ,
CD271 is an imperfect marker for melanoma initiating cells, Oncotarget, vol.5, pp.5272-5283, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02530580
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth, Cancer Res, vol.71, pp.3098-3109, 2011. ,
A stress-induced early innate response causes multidrug tolerance in melanoma, Oncogene, vol.34, pp.4448-4459, 2014. ,
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271, Nature, vol.466, pp.133-137, 2010. ,
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors, Cancer Discov, vol.4, pp.816-827, 2014. ,
PDGFRalpha upregulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation, Oncotarget, vol.5, pp.1926-1941, 2014. ,
In vitro and in vivo anti-melanoma effects of ciglitazone, J Invest Dermatol, vol.129, pp.1208-1218, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-02194090
Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor, Oncotarget, vol.4, pp.1986-1998, 2013. ,
Metformin blocks melanoma invasion and metastasis development in a p53-dependent manner, Mol Cancer Ther, vol.12, pp.1605-1615, 2013. ,
Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth, Cell Death Differ, vol.18, pp.109-121, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00551041
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms, Cell Death Dis, vol.2, p.199, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-02530686